Clever Leaves is a Colombia-based cultivator, extractor, and exporter of pharmaceutical-grade medical cannabis products. The company grows cannabis in large-scale greenhouses in Colombia and processes it into dried flower and extracted products — including oils, isolates, standardized extracts, and oral solutions — which it exports to medical cannabis markets worldwide. Clever Leaves sells on a B2B basis to pharmaceutical companies, licensed distributors, and pharmacy chains, who then distribute products to patients through regulated medical channels. Key markets include Australia, Brazil, Germany, Israel, and the United Kingdom. Following the sale of its nutraceutical business (Herbal Brands) in early 2024, Clever Leaves is now a pure-play cannabinoid company. Revenue is driven by export volumes, product mix, and geographic expansion — each new country that approves Colombian cannabis imports is a new revenue source, with growth coming in steps as regulatory clearances are obtained. A central element of Clever Leaves' business model is its low-cost Colombian production base: year-round sunlight, high elevation, and low labor costs allow the company to produce at significantly lower cost per gram than Canadian or European peers. GMP certifications from the EU, Colombia, Brazil, and Australia are prerequisites for selling into regulated pharmaceutical markets, making certification maintenance a key operational priority. The company's growth strategy focuses on expanding dried flower exports, deepening penetration in its six core markets, and positioning itself to enter new markets as medical cannabis regulations evolve globally.